NCT00425581 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bar-Oz B, Lev-Sagie A, Arad I, Salpeter L, Nir A
N-terminal pro-B-type natriuretic peptide concentrations in mothers just before delivery, in cord blood, and in newborns. Clin Chem. 2005 May;51(5):926-7.
Cowie MR, Mendez GF
BNP and congestive heart failure. Prog Cardiovasc Dis. 2002 Jan-Feb;44(4):293-321. Review.
Mäkikallio K, Vuolteenaho O, Jouppila P, Räsänen J
Ultrasonographic and biochemical markers of human fetal cardiac dysfunction in placental insufficiency. Circulation. 2002 Apr 30;105(17):2058-63.
Nasser N, Bar-Oz B, Nir A
Natriuretic peptides and heart disease in infants and children. J Pediatr. 2005 Aug;147(2):248-53. Review.
Puddy VF, Amirmansour C, Williams AF, Singer DR
Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond). 2002 Jul;103(1):75-7.

N-Terminal Pro-B-Type and Cardiac Troponin T Levels for Monitoring Effectiveness of Treatment in Very Low Birth Weight Infants With Hemodynamic Instability

Details for clinical trial NCT00425581

Clinical trial NCT00425581 - References